November 14, 2007 - Safeway Inc. and the Prostate Cancer Foundation will announce a major joint gift to launch a landmark research initiative for prostate cancer Thursday, Nov.15, 2007 at the U.S. Chamber of Commerce in Washington, DC.

The S.T.A.R. Program (for Special Team Amplification of Research) will bring together an interdisciplinary team of investigators from Johns Hopkins, University of Michigan Cancer Center, University of British Columbia, University of Washington, and M.D. Anderson Cancer Center (Houston) and four other research partners. S.T.A.R. team members will explore the role of targeted heat in cancer therapy, using nanotechnology and other mechanisms, to treat prostate cancer.

The forum may be viewed live at www.uschamber.com/webcasts.

Participants include:
- Steve Burd, Chairman, President and CEO, Safeway Inc.
- Michael Milken, Chairman, The Milken Institute
- Jonathan W. Simons, M.D., CEO and President, David H. Koch Chair, Prostate Cancer Foundation
- Robert Getzenberg, Ph.D., Professor and Director of Research,Brady Urological Institute, Johns Hopkins University School of Medicine
- Donald Coffey, Ph.D., Professor of Urology, Oncology, Pathology, Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine
-Representative Mike Rogers (R-MI)

For more information: www.prostatecancerfoundation.org


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now